国产首款球囊扩张式主动脉瓣膜Prizvalve®正式进入注册临床研究

2021年1月，纽脉医疗自主研发的Prizvalve®经导管主动脉瓣膜系统（以下简称“Prizvalve®系统”）顺利通过科技部遗传办备案（备案号：2021BAL0040）审批，正式开始进入注册临床研究阶段。Prizvalve®系统全国多中心注册临床研究由四川大学华西医院心脏内科陈茂主任牵头，期待这款国产第一个球扩式瓣膜能够尽快为中国的患者和医生提供新的瓣膜解决方案。

中国首款二尖瓣置换系统Mi-thos®正式进入注册临床研究

2021年1月Mi-thos®经导管二尖瓣置换系统（简称“Mi-thos®”）顺利通过科技部遗传办备案审批（遗传办备案号2021BAL0042），宣布正式进入注册临床研究阶段。Mi-thos®是由上海纽脉医疗和国家生物医学材料工程技术研究中心张兴栋院士团队、中山医院王春生主任牵头，与阜外医院、西京医院等医学团队联合技术攻关，获得国家“十三五”课题和上海市科委科技创新行动计划支持，累计申请42项国家专利，历经多年开发成功的一款产品。Mi-thos®有望成为中国首款上市的经导管介入二尖瓣置换的产品，造福广大的二尖瓣反流（MR）疾病患者。

Jumpcode Genomics Secures $21M in Series B Funding

Jumpcode Genomics – a genome technology company focused on improving the understanding of human disease – today announced it raised $21 million in a Series B round of funding. The round was co-led by Baird Capital and Arboretum Ventures and included existing investor LYZZ Capital. Jumpcode also announced the appointment of Frank Witney to its Board of Directors, further expanding the company’s leadership team. Additionally, the company announced the move of its headquarters into larger office and laboratory space.

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

SAN DIEGO, December 3, 2020 – Qpex Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, announced today that it has initiated a Phase 1 clinical study of QPX7728, its novel ultra-broad-spectrum beta-lactamase inhibitor.

捍宇医疗完成总额为5亿人民币D轮融资

2020年8月13日，捍宇医疗于当日正式宣布完成总额为5亿人民币D轮融资。本轮融资由弘晖资本，CPE，盈科资本联合领投，朗姿韩亚，朗玛峰，幂方资本，东证资本，泰福资本，合方科创以及春风创投跟投。筹集的资金将用于推动公司领先产品Valve Clamp的上市，以及新产品的持续研发

NEURELIS ANNOUNCES RAPID AND BROAD PAYER COVERAGE OF THE COMPANY'S FLAGSHIP PRODUCT, VALTOCO® (DIAZEPAM NASAL SPRAY)

— More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older
— Neurelis' patient assistance program supports eligible patients who have no health insurance
— Co-pay program for VALTOCO helps commercial patients lower their out-of-pocket costs to as low as $20